0000899243-20-032667.txt : 20201203 0000899243-20-032667.hdr.sgml : 20201203 20201203160508 ACCESSION NUMBER: 0000899243-20-032667 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201201 FILED AS OF DATE: 20201203 DATE AS OF CHANGE: 20201203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Henn Matthew R. CENTRAL INDEX KEY: 0001767321 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 201366943 MAIL ADDRESS: STREET 1: C/O SERES THERAPEUTICS, INC. STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-01 0 0001609809 Seres Therapeutics, Inc. MCRB 0001767321 Henn Matthew R. C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Common Stock 2020-12-01 4 M 0 26000 0.71 A 38000 D Common Stock 2020-12-01 4 M 0 26250 9.89 A 64250 D Common Stock 2020-12-01 4 M 0 27562 6.01 A 91812 D Common Stock 2020-12-01 4 S 0 55706 26.56 D 36106 D Common Stock 2020-12-01 4 S 0 26265 27.56 D 9841 D Common Stock 2020-12-01 4 S 0 9841 28.34 D 0 D Stock Option (Right to Buy) 0.71 2020-12-01 4 M 0 26000 0.00 D 2016-09-19 2024-08-06 Common Stock 26000 0 D Stock Option (Right to Buy) 9.89 2020-12-01 4 M 0 26250 0.00 D 2024-08-06 Common Stock 26250 3750 D Stock Option (Right to Buy) 6.01 2020-12-01 4 M 0 27562 0.00 D 2029-01-24 Common Stock 27562 45938 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.07 to $27.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.10 to $28.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.145 to $28.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option has vested as to 25% of the shares on January 26, 2018. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter. The option has vested as to 25% of the shares on January 25, 2020. The remainder of the shares will vest or have vested in 12 equal quarterly installments thereafter. Chief Scientific Officer and EVP /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn 2020-12-03